MEDICAL CHEMICAL DEFENSE (SDD)

Abstract

This Project provides for the development of medical materiel and other medical equipment items necessary to provide an effective capability for medical defense against chemical agent threats facing U.S. forces in the field. This project supports efforts in the Engineering and Manufacturing Development (EMD) phase of the acquisition strategy for prophylactic, pre-treatment, and therapeutic drugs and diagnostic medical devices for the protection, treatment, detection and medical management of chemical warfare agent exposures. Project funds research and development of safety studies, manufacturing scale-up, process validation, drug interaction, performance test, and submission of the Food and Drug Administration (FDA) drug licensure application(s). This program currently funds: (1) Advanced Anticonvulsant System (AAS), which consists of the drug midazolam in an autoinjector, to be used as a treatment for nerve agent-induced seizures and will be a replacement for the currently-fielded Convulsant Antidote for Nerve Agent (CANA) autoinjector, which uses diazepam; (2) Bioscavenger, a new capability, to be used as a prophylaxis against nerve agents; (3) Inhalation Atropine (IA), an improvement to an existing capability leveraging novel delivery, to be used to treat continuing nerve agent-induced effects after the patient has been evacuated to a medical treatment facility; (4) Improved Nerve Agent Treatment System (INATS), a replacement and improvement to an existing capability, to be used as a treatment for nerve agent intoxication and includes obtaining new indications for Pyridostigmine Bromide (PB) to be integrated with current therapeutic regimens; and (5) Pharmaceutical Post Approval and Development Support (PPADS) which provides operations and sustainment support of fielded medical countermeasure to include Soman Nerve Agent Pyridostigmine Pretreatment. Time and Temperature Indicators (TTIs), Item Unique Identification (IUID), and Radio-Frequency Identification (RFID) will be incorporated into the development effort of all medical countermeasures developed by the Medical Identification and Treatment Systems Joint Product Management Office. A TTI is a human readable tab that will provide the Warfighter immediate knowledge if the product is still useable or not. IUID and RFID labels placed medical countermeasures improve inventory management and strategic purchasing, and enable reliable visibility, and capability-based operational readiness.

Open PDF

Document Details

Document Type
Project
Publication Date
Oct 01, 2012
Source ID
MC5_0604384BP_5_0400_PB_2012

Tags

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Logistics and Supply Chain Management.
  • Neurotoxicology

Related Documents